T2 Biosystems Announces 2017 Second Quarter Financial and Operational Results Release and Conference Call Date

LEXINGTON, Mass., July 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 second quarter financial and operational results after the market closes on Thursday, August 3, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, August 3, 2017, to discuss the financial results and other business developments.

Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.

About T2 Biosystems
T2 Biosystems is dedicated to developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

Company Contact: Darlene Deptula-Hicks, T2 Biosystems SVP & Chief Financial Officer ddeptula@t2biosystems.com 603-553-5803 Media Contact: Matthew McKillip, T2 Biosystems mmckillip@t2biosystems.com 518-577-3466 Investor Contact: Chris Brinzey, Westwicke Partners chris.brinzey@westwicke.com 339-970-2843

Source:T2 Biosystems, Inc.